Concepedia

Pharmacoeconomic analysis of paliperidone palmitate for treating schizophrenia in Greece

Thomas R. Einarson, Maria Geitona, A Chaidemenos, V. Karpouza, Theodoros Mougiakos, P. Paterakis, Dimitrios Ploumpidis, Dionyssios Potamitis-Komis, Roman Zilbershtein, Colin Vicente,

Annals of General Psychiatry · 2012 · 26 citations · 33 references

DOIFull text

Open access

Abstract

PP-LAI appears to be a cost-effective option for treating chronic schizophrenia in Greece compared with RIS-LAI since it results in savings to the health care system along with better patient outcomes.

References

33

Medication Adherence and Long-Term Functional Outcomes in the Treatment of Schizophrenia in Usual Care

Haya Ascher‐Svanum, Douglas E. Faries, Baojin Zhu et al. · The Journal of Clinical Psychiatry · 2006 · 476 citations

Long-Acting Injectable Risperidone: Efficacy and Safety of the First Long-Acting Atypical Antipsychotic

John M. Kane, Mariëlle Eerdekens, Jean‐Pierre Lindenmayer et al. · American Journal of Psychiatry · 2003 · 474 citations

Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia

Gunnar Morken, Jan H. Widen, Rolf W. Gråwe · BMC Psychiatry · 2008 · 295 citations · Full text

Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled study

David Hough, Srihari Gopal, Ujjwala Vijapurkar et al. · Schizophrenia Research · 2009 · 249 citations

, , +7

A Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of 3 Doses of Paliperidone Palmitate in Adults With Acutely Exacerbated Schizophrenia

Gahan Pandina, Jean‐Pierre Lindenmayer, Julia Lull et al. · Journal of Clinical Psychopharmacology · 2010 · 199 citations

, , +16